FY2030 Earnings Estimate for STOK Issued By HC Wainwright

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Stoke Therapeutics in a research note issued on Friday, March 20th. HC Wainwright analyst A. Ghosh anticipates that the company will earn $4.03 per share for the year. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Several other equities analysts have also recently commented on the stock. Loop Capital set a $35.00 target price on shares of Stoke Therapeutics in a research report on Monday, January 5th. Needham & Company LLC boosted their target price on Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Chardan Capital reaffirmed a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 18th. UBS Group set a $50.00 price target on Stoke Therapeutics in a research report on Monday, December 15th. Finally, Canaccord Genuity Group lifted their price target on Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $41.83.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $33.51 on Monday. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $40.22. The firm’s 50-day simple moving average is $32.61 and its 200 day simple moving average is $30.17. The stock has a market cap of $1.98 billion, a PE ratio of 50.01 and a beta of 1.07.

Insiders Place Their Bets

In other news, General Counsel Jonathan Allan sold 4,628 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $145,041.52. Following the completion of the sale, the general counsel owned 28,836 shares in the company, valued at $903,720.24. This trade represents a 13.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Thomas Leggett sold 2,382 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $74,651.88. Following the sale, the chief financial officer owned 10,172 shares of the company’s stock, valued at approximately $318,790.48. The trade was a 18.97% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 69,699 shares of company stock valued at $2,526,714. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC bought a new stake in shares of Stoke Therapeutics in the fourth quarter valued at $26,000. Harbour Investments Inc. lifted its position in shares of Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the last quarter. Generali Investments Management Co LLC bought a new position in shares of Stoke Therapeutics during the 3rd quarter worth $41,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Stoke Therapeutics by 31.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after acquiring an additional 658 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares during the last quarter.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.